Considering those pathways beyond the UPR, RNA-seq analyses demonstrated that treatment with NXP800 impacted other key pathways, including AR, MYC, and E2F activity, implicated in prostate cancer treatment resistance (63, 66, 73). Here, MYC is linked to prostate carcinoma.